SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS (tradipitant), hailed as the first new motion sickness drug in over 40 years. The community is buzzing about its substantial potential to address GLP-1 induced nausea and vomiting, viewing this as a significant market expansion that could drive a revaluation of the company. With additional pipeline catalysts anticipated, many are expressing strong conviction in its future growth, despite some predicting immediate profit-taking.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amid intense community debate, largely driven by ongoing price depreciation attributed to tax loss harvesting and persistent selling pressure from SPAC-related share overhang. Despite recent inclusion in the Russell 2000/3000 indexes and reported strong revenue growth in its latest quarter, sentiment remains highly polarized. Bulls view the stock as deeply undervalued with significant long-term potential from user growth and international expansion, while bears warn of continued dilution and question the company's valuation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid sharp investor division, primarily driven by the recent FDA approval of Novo Nordisk's oral Wegovy pill and speculation around potential distribution partnerships for GLP-1 treatments. While many note the stock's significant drawdown and high short interest as bearish indicators, others view the current valuation as a prime long-term buying opportunity, citing strong fundamentals, institutional accumulation, and the company's expansion into new health verticals and international markets. The community is actively debating whether the current dip sets the stage for a short squeeze or further decline for the direct-to-consumer telehealth provider.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amidst growing investor frustration as the stock continues to mark new lows, fueling intense debate around its management team and the prolonged absence of a permanent CEO. The community is actively discussing the disconnect between the acclaimed vehicle technology and the company's market performance, with many questioning impending production targets and speculating on potential short squeezes or further strategic shifts.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively debated amid its significant price volatility, with many investors anticipating potential breakthroughs and new partnerships at the upcoming CES 2026. While some highlight its robust contractual backlog, growing revenues in voice AI, and debt-free status as a compelling buying opportunity, others express deep skepticism regarding management's communication and the stock's recent performance.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is capturing market attention following a proposed business combination with Applied Digital, which would see Applied Digital's cloud GPU business spun off into ChronoScale, an AI compute platform. The potential "AI merger" is fueling fervent discussion among traders, with many anticipating a significant run due to the stock's low float, while others express concerns about potential shareholder dilution.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is at the center of investor attention with a highly anticipated regulatory decision for its Cushing's syndrome drug, relacorilant, prompting intense community debate and significant trading volume. Traders are closely watching for an approval or a potential Complete Response Letter, weighing recent sector approvals against CORT's price action and broader pipeline, including its ovarian cancer program, which fuels long-term bullish sentiment despite short-term uncertainty.

Themes ETF Trust - Leverage Shares 2X Long UNH Daily ETF

Leverage Shares 2X Long UNH Daily ETF

UNHG is trending amid widespread investor frustration over a significant price drop that appears decoupled from the performance of its underlying asset, UNH. The community is actively discussing a recent dividend event, which many perceive as fund manipulation or unusual decay rather than a true payout, raising serious concerns about the leveraged ETF's tracking accuracy. This has fueled a broader debate on the legitimacy and reliability of this relatively new 2x leveraged offering, with many advising caution against long-term positions.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics (RNAZ) is trending following its strategic acquisition of Polynoma and significant financing from CK Life Sciences, which positions the company to advance its lead microRNA candidate, TTX-MC138, into Phase 2 trials. This news has ignited intense community debate, with some anticipating a significant short squeeze and breakthrough clinical updates, while others express deep skepticism regarding potential dilution, the terms of the acquisition, and the value of the associated Contingent Value Rights (CVR) agreement.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to significant community discussion surrounding an ongoing, repeatedly postponed proxy vote on share authorization, creating considerable market uncertainty. Investors are sharply divided, with many expressing frustration over potential dilution and management's communication, while others advocate for the shares as crucial for strategic acquisitions like Ask Sage and future growth. Despite current price stagnation, a core of optimism persists for the company's potential to secure substantial government contracts and leverage its AI capabilities within the defense and national security sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Castellum, Inc. is a technology firm. It operates in the development of strategic acquisitions in cyber security, information technology, information warfare, electronic warfare, software engineering, data analytics and program support. The company was founded on September 30, 2010 and is headquartered in Vienna, MD.

Current Price	$0.93
Prev Close	$0.9593
Open	$0.9659
Dividend Yield	0.00%
50-Day Moving Average	$1.08
Beta	1.13
Avg. Volume	3.52M
PE Ratio	-14.65

52-Week High	$2.00
52-Week Low	$0.6126
Market Capitalization	$90.76M
EPS (Annual)	-$0.1827
Price to Book	2.40
Revenue Per Employee	$188,087.61
Enterprise Value/EBITDA	N/A

ONOV
Castellum Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ONOV News

ONOVCastellum Inc